Skip to main content
OpenTrials

Clinical trial condition

Neoplastic Processes

Explore clinical trials studying Neoplastic Processes. Study availability and eligibility vary by location and protocol.

3,300 public trials 694 recruiting studies
Refine in advanced search Browse all conditions

Neoplastic Processes trial results

Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +17 more
Locations
  • City of Hope Phoenix, Arizona, United States
  • City of Hope Duarte, California, United States
  • Medical Oncology Hematology Consultants Newark, Delaware, United States
  • Hematology Oncology Associates of the Treasure Coast Port Saint Lucie, Florida, United States
View all 43 locations
View Trial Details
Recruiting

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

NCT05929222

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico Sassuolo, Modena (MO), Italy
  • Azienda Ospedaliera Nazionale Ss Antonio E Biagio E C Arrigo, SCDU Ematologia Alessandria, Italy
  • AORN San Giuseppe Moscati Avellino, U.O.C. Ematologia e Trapianto Emopoietico Avellino, Italy
  • Centro Di Riferimento Oncologico Di Aviano, S.O.C. Oncologia Medica e dei Tumori Immunocorrelati Aviano, Italy
View all 49 locations
View Trial Details
Recruiting

NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

NCT07563829

Conditions
Metastatic Malignant Neoplasm, Neoplasm Metastasis, Neoplasms, +3 more
Locations
  • University of California - San Diego La Jolla, California, United States
  • Johns Hopkins Baltimore, Maryland, United States
  • Montefiore The Bronx, New York, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View Trial Details
Recruiting

Somatostatin Receptor PET/CT in SSTR-Related Disease Patients

NCT06690957

Conditions
Metastasis, Neoplasm Metastasis, Neoplasms, +6 more
Locations
  • Tianjin Medical University General Hospital Tianjin, Tianjin Municipality, China
  • The First Affiliated Hospital of University of Science and Technology of China Hefei, Anhui, China
  • The Affiliated Hospital of Qingdao University Qingdao, Shandong, China
View Trial Details
Recruiting

Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases

NCT06690736

Conditions
CXCR4-related Disease, Metastasis, Neoplasm Metastasis, +6 more
Locations
  • Tianjin Medical University General Hospital Tianjin, Tianjin Municipality, China
  • The First Affiliated Hospital of University of Science and Technology of China Hefei, Anhui, China
  • The Affiliated Hospital of Qingdao University Qingdao, Shandong, China
View Trial Details
Recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685

Conditions
Adenocarcinoma, Advanced Solid Tumor, Bronchial Neoplasms, +21 more
Locations
  • UCLA Santa Monica, California, United States
  • University of Colorado Health Hospital Aurora, Colorado, United States
  • Sarah Cannon Research Institute at HealthOne Denver, Colorado, United States
  • Florida Cancer Specialists ORLANDO/DDU Lake Mary, Florida, United States
View all 33 locations
View Trial Details
Recruiting

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

NCT04585958

Conditions
Metastatic Malignant Solid Neoplasm, Neoplasm Metastasis, Neoplasms, +5 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Emory University Hospital Midtown Atlanta, Georgia, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
View all 13 locations
View Trial Details
Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328

Conditions
Breast Diseases, Breast Neoplasms, ER-Positive HER2-Negative Breast Cancer, +8 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site Marietta, Georgia, United States
  • Research Site Evanston, Illinois, United States
View all 89 locations
View Trial Details

Related conditions